Delamanid is Indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Delamanid was developed by Otsuka Pharmaceutical Co. Ltd..
The API has now reached off-patent status, after being launched in 2014.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Delamanid was exported from India in 2023 , with an average price over the period of $148060 /kg.
The key suppliers were Microlabs, with a focus on markets in Europe.

For enquiries regarding more detailed trade data of Delamanid and many others, contact info@pharmacheminvestor.com